Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sarepta licenses Pompe program from Lacerta, options two CNS candidates

Executive Summary

Sarepta Therapeutics Inc. licensed exclusive worldwide rights to Lacerta Therapeutics Inc.'s gene therapy candidate for Pompe disease (an autosomal recessive metabolic disorder which damages muscle and nerve cells) and has options to license two additional neuro-focused candidates from Lacerta's pipeline.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register